MetaVia Inc. Common Stock (MTVA)
Stock · NASDAQ · Health Care
$1.71as of 8/28/2026
Price chart
Open in TradingViewActive signals
Support level
$1.41
Industry
Biotechnology: Pharmaceutical Preparations
About MTVA
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 cli…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 8
- Website
- metaviatx.com/
Fundamentals
- 1-day range
- $1.44$1.5
- Market cap
- $7.49M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-6.03
- Dividend yield
- —
- Beta
- 0.94
- Avg. volume
- 2.48M
- Dividend pay date
- December 31, 2019
52-week range
$0.9661$19.03
Forecasts
2 analyst ratings
Buy 88%
Hold 13%
Sell 0%
1-year price forecast
High
$30
+1654.4%
Median
$25
+1362.0%
Low
$20
+1069.6%
MetaVia Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- MTVAMetaVia Inc. Common Stock$1.71▲ 3.01%Market cap $7.49MP/E —$0.9661$19.03
- CNSPCNS Pharmaceuticals Inc. Common Stock$5.52▲ 0.11%Market cap $7.65MP/E —$1.9$10.59
- PCSAProcessa Pharmaceuticals Inc. Common Stock$2.07▼ 1.90%Market cap $7.65MP/E 3.31$1.67$14.24
- APUSApimeds Pharmaceuticals US Inc. Common Stock$3.87▼ 1.28%Market cap $7.29MP/E —$3.39$403.1
- APREAprea Therapeutics Inc. Common stock$0.8387▼ 2.48%Market cap $7.83MP/E —$0.548$1.69
- SNGXSoligenix Inc. Common Stock$0.38▲ 0.00%Market cap $8.24MP/E —$0.28$3.22
- IMNNImunon Inc. Common Stock$1.58▼ 1.25%Market cap $6.64MP/E —$1.47$6.35
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MTVA MetaVia Inc. Common Stock | $7.49M | — | $1.71 | ▲ 3.01% | $0.9661$19.03 |
| CNSP CNS Pharmaceuticals Inc. Common Stock | $7.65M | — | $5.52 | ▲ 0.11% | $1.9$10.59 |
| PCSA Processa Pharmaceuticals Inc. Common Stock | $7.65M | 3.31 | $2.07 | ▼ 1.90% | $1.67$14.24 |
| APUS Apimeds Pharmaceuticals US Inc. Common Stock | $7.29M | — | $3.87 | ▼ 1.28% | $3.39$403.1 |
| APRE Aprea Therapeutics Inc. Common stock | $7.83M | — | $0.8387 | ▼ 2.48% | $0.548$1.69 |
| SNGX Soligenix Inc. Common Stock | $8.24M | — | $0.38 | ▲ 0.00% | $0.28$3.22 |
| IMNN Imunon Inc. Common Stock | $6.64M | — | $1.58 | ▼ 1.25% | $1.47$6.35 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- MTVA: Dose Titration Complete in Phase 1 Part 3 Study of DA-1726Yahoo · 8/12/2026
- MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateYahoo · 8/6/2026
- MetaVia Q2 EPS $(0.90) Misses $(0.82) EstimateBenzinga · 8/6/2026
Insider Activity
Insider Actions →Acquired
103.1K
Disposed
0
- Michael Salsbury · June 8, 2026 · Grant17.2K
- James Patrick Tursi · June 8, 2026 · Grant17.2K
- Jason L. Groves · June 8, 2026 · Grant17.2K
- Mark A. Glickman · June 8, 2026 · Grant17.2K
- Andrew I. Koven · June 8, 2026 · Grant17.2K
- D. Gordon Strickland · June 8, 2026 · Grant17.2K
Institutional Ownership
March 31, 2026
- Total shares held
- 60.1K
- Total value held
- $72.1K
- Institutional holders
- 11
Top holders this quarter
- Unknown33.6K
- Unknown10.9K
- Unknown10.0K
- Unknown2.6K
- Unknown2.2K
- Unknown479
- Unknown205
- Unknown3
- Unknown2
- Unknown2
See the full, filterable feed with live charts on the MarketWall dashboard.